RxDoctor Payments Data

Yvonne Monroe, MD

Psychiatry · Durham, NCNPI 1710084967

Payments from drug & device makers

$2,357in general payments, 2019–2025

Across 126 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$298
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$290
  • Takeda Pharmaceuticals U.S.A., Inc.$242
  • AbbVie$198
  • Johnson & Johnson$176
  • Otsuka America Pharmaceutical, Inc.$160
  • plus $993 from 15 others

What the payments were for

  • Food & beverage$2,33099%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,357 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,780
Medicare patients
48
Services billed
699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide25$11,560
Vilazodone Hcl48$4,380
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine45$2,038
Gabapentin74$1,529
Desvenlafaxine Succinate ErDesvenlafaxine Succinate42$1,513
Oxazepam17$1,505
Duloxetine Hcl64$1,434
Bupropion XlBupropion Hcl50$919
Venlafaxine Hcl ErVenlafaxine Hcl19$883
Liothyronine Sodium16$807
Clonazepam98$784
Paliperidone ErPaliperidone13$753
Quetiapine Fumarate49$752
Lamotrigine52$673
Alprazolam37$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$242$11,56025 claims
AbbVieSynthroid$198$23011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →